BioMedTracker is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Informa
Menu

Report Library

All Reports
Datamonitor Healthcare CV&Met Disease Analysis: Non-Alcoholic Steatohepatitis (NASH)

October 14, 2020

Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of patients who have fatty liver in the absence of significant alcohol consumption. NAFLD patients are often segmented into non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) patients. NAFLD diagnosis requires evidence of hepatic steatosis and lack of secondary causes of liver fat accumulation such as substantial alcohol consumption, long-term use of a steatogenic medicine, or monogenic hereditary disorders. NASH is defined as the presence of >5% hepatic steatosis and inflammation with hepatocyte injury, with or without fibrosis. Although the presence of fibrosis is not required for a diagnosis of NASH, fibrosis is present in over 80% of NASH patients. For this reason, NASH patients are often further segmented by their fibrosis stage.

NASH represents a great clinical burden due to the high liver-related and non-liver-related mortality rates associated with the disease. Moreover, advanced NASH patients are at increased risk of developing cirrhosis, which is linked to liver decompensation, end-stage liver disease, and hepatocellular carcinoma. Consequently, NASH is set to become the most common indication for liver transplant in the US, which creates a significant economic burden on healthcare systems, therefore augmenting the urgency to find an efficacious therapy.

This Datamonitor Healthcare report contains a Disease Analysis module.
 

Indications Covered: Non-Alcoholic Steatohepatitis (NASH)
Back to the top Back to the top